


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (REV. 9-2001)		ATTORNEY'S DOCKET NUMBER 20740-242738
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) T01/009059 To Be Assigned
INTERNATIONAL APPLICATION NO. PCT/EP00/05127	INTERNATIONAL FILING DATE June 5, 2000	PRIORITY DATE CLAIMED June 4, 1999
TITLE OF INVENTION RECOMBINANT FUSION PROTEIN, (VACCINE) COMPOSITION CONTAINING THE SAME AND METHOD FOR THE PRODUCTION THEREOF		
APPLICANT(S) FOR DO/EO/US LOHMANN ANIMAL HEALTH GMBH & CO. KG		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 20 below concern document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>		

U.S. APPLICATION NO (37 CFR 1.492) To Be Assigned 101009059		INTERNATIONAL APPLICATION NO. PCT/EP00/05127	ATTORNEY'S DOCKET NUMBER 20740-242738
<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p>		CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$890.00	
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p>		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	- 20 =	8	x \$18.00
Independent claims	- 3 =	1	x \$84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$280.00	
TOTAL OF ABOVE CALCULATIONS =		\$	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		+	
SUBTOTAL =		\$	
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>		\$ 130.00	
TOTAL NATIONAL FEE =		\$	
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property</p>		+	
TOTAL FEES ENCLOSED =		\$ 1,528.00	
		Amount to be refunded:	\$
		charged:	\$
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-0029</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input checked="" type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>			
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO: Paul W. Busse Faegre & Benson LLP 2200 Wells Fargo Center 90 South Seventh Street Minneapolis, MN 55402-3901</p>			
 SIGNATURE <u>Paul W. Busse</u> NAME <u>32,403</u> REGISTRATION NUMBER			

10/009059
JCIS Rec'd PCT/PTO 03 DEC 2001

Attorney Docket No. 20740-242738

IN THE UNITED STATES PATENT OFFICE (EO/US)


International Application No.	International Filing Date	Priority Date Claimed
PCT/EP00/05127	5 June 2000	4 June 1999
Title of Invention		
RECOMBINANT FUSION PROTEIN, (VACCINE) COMPOSITION CONTAINING THE SAME AND METHOD FOR THE PRODUCTION THEREOF		
Applicant		
LOHMANN ANIMAL HEALTH GMBH & CO. KG		

Box PCT
Commissioner for Patents
Washington, D.C. 20231

ATTENTION: EO/US

EXPRESS MAIL LABEL NO. EL208377544US

I CERTIFY THAT, ON DECEMBER 3, 2001, THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL POST OFFICE TO ADDRESSEE SERVICE UNDER 37 C.F.R. 1.10 IN AN ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.


Jamie A. Ebach

**TRANSMITTAL LETTER
ENTRY INTO U.S. NATIONAL STAGE UNDER PCT CHAPTER II**

Sir:

The Applicant hereby requests that the United States Elected Office begin national stage examination procedures for the above-identified international application under 35 U.S.C. 371. Pursuant to 35 U.S.C. 371(f), it is expressly requested that these procedures commence immediately. Enclosed in connection with this request are the following documents:

1. Credit Card Payment form in the amount of \$1,528.00 for the basic national fee and other fees required for filing (1 page);
2. Transmittal Letter to the U.S. Designated/Elected Office form PTO-1390 and a duplicate copy as requested (3 pages);
3. PCT Request (5 pages) including: Form RO/101 (1 page), Specification (17 pages), Claims (5 pages), Abstract (1 page), Form RO/134 (1 page), Form DSMZ-BP/1 with attachments (7 pages), Form DSMZ-BP/4 (2 pages) and DSMZ-BP/9 (2 pages);
4. Copy of Official Filing Receipt (1 page);
5. Form PCT/RO/105 (1 page);
6. FORM PCT/RO/106 (2 pages);

10 / 009059
JC13 PCT/PTO 03 DEC 2001

7. FORM PCT/ISA/202 (1 page);
8. FORM PCT/IB/301 (3 pages);
9. FORM PCT/ISA/220 and PCT/ISA/210 (9 pages);
10. FORM PCT/ISA/213 (1page);
11. FORM PCT/IPEA/401 (4 pages);
12. FOR PCT/IPEA/402 (1 page);
13. Copy of WO 00/75345 with published ISR (7 pages);
14. FORM PCT/IB/308 (1 page);
15. FORM PCT/IPEA/408 and FORM PCT/IB/332 (6 pages);
16. FORM PCT/IPEA/409 (11 pages);
17. Copies of Response to Written Opinion filed on 4/18/2001 (10 pages);
18. Postcard.

Enclosed is our credit card payment form in the amount of \$1,528.00. In the event the amount submitted herewith is insufficient with respect to placing the application on file, the Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 06-0029 and is requested to notify us of the same.

Respectfully Submitted,

LOHMANN ANIMAL HEALTH
GMBH & CO. KG

By:


John M. Haurykiewicz #29,311
FAEGRE & BENSON LLP
2200 Wells Fargo Center
90 South Seventh Street
Minneapolis, MN 55402-3901
612/766-8216

Dated: 3 December 2001

M2:20428425.01